<p>CSPC PHARMA (01093.HK) announced that its subsidiary, CSPC Innovation, is selling its non-core business - a 30.0704% stake in Beijing Guoxin Huijin, which operates a full-media communication business platform, for a cash consideration of 230 million RMB. The estimated loss from the sale is approximately 15 million RMB</p>

510660

159849

159837

<p>CSPC PHARMA announced that its subsidiary, CSPC Innovation, will sell its non-core business - a 30.0704% stake in Beijing Guoxin Huijin, which operates a full media communication business platform, for a cash consideration of 230 million RMB. The estimated loss from the sale is approximately 15 million RMB</p>

AASTOCKS

ChinaAMC SSE Health Care ETF Initiating Fund

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP CSI Pharmaceuticals ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

CSPC PHARMA

Guotai CSI Bio-medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

CSPC PHARMA's subsidiary sells core business for 230 million RMB